Amneal Pharmaceuticals has been added to the S&P SmallCap 600 Index effective January 30, 2026, reflecting its financial performance.
Quiver AI Summary
Amneal Pharmaceuticals, Inc. announced its addition to the S&P SmallCap 600® Index, effective January 30, 2026. This index is a recognized benchmark for U.S. small-cap equities, used by investors seeking companies with strong market performance and sustained profitability. Amneal's inclusion underscores its consistent financial performance and adherence to the index's criteria. Executives at Amneal expressed satisfaction with the recognition, indicating it enhances the company’s visibility among investors and may lead to increased trading liquidity. Amneal is a global biopharmaceutical company offering a wide range of products, including pharmaceuticals and complex injectables, and is focused on expanding its market presence.
Potential Positives
- Amneal Pharmaceuticals has been added to the prestigious S&P SmallCap 600® Index, which enhances its visibility within the investment community.
- This inclusion is a testament to Amneal's consistent operating and financial performance, indicating the company's growth and stability.
- Being part of the S&P SmallCap 600 Index is likely to increase trading liquidity and broaden Amneal's investor base over time.
- The recognition aligns Amneal with a select group of pharmaceutical and biotechnology companies, which may attract the attention of potential investors.
Potential Negatives
- None
FAQ
When will Amneal be added to the S&P SmallCap 600 Index?
Amneal will be included in the S&P SmallCap 600 Index effective prior to the market open on January 30, 2026.
What does inclusion in the S&P SmallCap 600 Index mean for Amneal?
Inclusion signifies Amneal's strong performance and enhances its visibility and liquidity among investors in the small-cap segment.
What criteria does the S&P SmallCap 600 Index use for selection?
The index uses criteria like market capitalization, liquidity, sector representation, and sustained profitability for selection of companies.
Who commented on Amneal's inclusion in the index?
Tasos Konidaris, Executive Vice President and CFO of Amneal, expressed the company's satisfaction with the inclusion.
What services does Amneal Pharmaceuticals provide?
Amneal develops, manufactures, and distributes over 290 pharmaceuticals, focusing on various therapeutic areas, including injectables and biosimilars.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$AMRX Insider Trading Activity
$AMRX insiders have traded $AMRX stock on the open market 13 times in the past 6 months. Of those trades, 0 have been purchases and 13 have been sales.
Here’s a breakdown of recent trading of $AMRX stock by insiders over the last 6 months:
- TASOS KONIDARIS (Executive Vice President & CFO) has made 0 purchases and 3 sales selling 499,730 shares for an estimated $4,663,070.
- NIKITA SHAH (Executive Vice President) has made 0 purchases and 5 sales selling 374,382 shares for an estimated $3,855,983.
- ANDREW S BOYER (Executive Vice President) has made 0 purchases and 2 sales selling 312,680 shares for an estimated $2,921,904.
- TED C NARK sold 50,000 shares for an estimated $586,000
- JOHN KIELY sold 32,000 shares for an estimated $295,360
- JASON B. DALY (EVP, Chief Legal Officer) sold 22,000 shares for an estimated $199,100
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$AMRX Revenue
$AMRX had revenues of $784.5M in Q3 2025. This is an increase of 11.68% from the same period in the prior year.
You can track AMRX financials on Quiver Quantitative's AMRX stock page.
$AMRX Hedge Fund Activity
We have seen 135 institutional investors add shares of $AMRX stock to their portfolio, and 103 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. added 1,942,294 shares (+16.0%) to their portfolio in Q3 2025, for an estimated $19,442,362
- MILLENNIUM MANAGEMENT LLC removed 1,710,276 shares (-33.9%) from their portfolio in Q3 2025, for an estimated $17,119,862
- ASSENAGON ASSET MANAGEMENT S.A. added 1,611,698 shares (+75.0%) to their portfolio in Q4 2025, for an estimated $20,307,394
- WESTSHORE WEALTH, LLC added 1,381,910 shares (+inf%) to their portfolio in Q3 2025, for an estimated $13,832,919
- BLACKBARN CAPITAL PARTNERS LP removed 1,257,118 shares (-36.5%) from their portfolio in Q3 2025, for an estimated $12,583,751
- MORGAN STANLEY added 1,005,848 shares (+40.3%) to their portfolio in Q3 2025, for an estimated $10,068,538
- SG AMERICAS SECURITIES, LLC added 758,343 shares (+2866.0%) to their portfolio in Q4 2025, for an estimated $9,555,121
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$AMRX Analyst Ratings
Wall Street analysts have issued reports on $AMRX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Piper Sandler issued a "Overweight" rating on 10/31/2025
To track analyst ratings and price targets for $AMRX, check out Quiver Quantitative's $AMRX forecast page.
$AMRX Price Targets
Multiple analysts have issued price targets for $AMRX recently. We have seen 3 analysts offer price targets for $AMRX in the last 6 months, with a median target of $14.0.
Here are some recent targets:
- Glen Santangelo from Barclays set a target price of $15.0 on 12/09/2025
- David Amsellem from Piper Sandler set a target price of $13.0 on 10/31/2025
- Chris Schott from JP Morgan set a target price of $14.0 on 09/16/2025
Full Release
BRIDGEWATER, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that it has been added to the S&P SmallCap 600 ® Index. The inclusion will become effective prior to the opening of trading on Friday, January 30, 2026.
Launched in 1994, the S&P SmallCap 600 Index is one of the most widely followed benchmarks for U.S. small-capitalization equities. The index is commonly used by active managers and small-cap investors seeking exposure to companies that meet disciplined criteria for market capitalization, liquidity, sector representation, and sustained profitability. Amneal’s inclusion reflects the Company’s consistent operating and financial performance and places it among a select group of pharmaceutical and biotechnology companies that meet the index’s screening requirements.
“We are pleased to be included in the S&P SmallCap 600 Index, which reflects the progress we have made executing our strategy and delivering consistent and growing financial performance,” said Tasos Konidaris, Executive Vice President and Chief Financial Officer of Amneal. “We believe this recognition enhances Amneal’s visibility within the investment community and supports the continued expansion of our investor base over time.”
Inclusion in the index is typically associated with increased trading liquidity and broader investor awareness for those seeking a more selective segment of the U.S. small-cap universe.
About Amneal
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, NJ, is a global biopharmaceutical company. We make healthy possible through the development, manufacturing, and distribution of a diverse portfolio of over 290 pharmaceuticals, primarily within the United States. In its Affordable Medicines segment, the Company is expanding across a broad range of complex product categories and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more information, please visit
www.amneal.com
and follow us on
LinkedIn
.
Investor Contact
Anthony DiMeo
VP, Investor Relations
[email protected]
Media Contact
Brandon Skop
Sr. Director, Corporate Communications
[email protected]
